2026 ICD-10-CM Diagnosis Code C90.02Multiple myeloma in relapse

ICD-10-CM Codes›C00–D49›C81-C96›C90

ICD-10-CM C90.02
CMSSource: CMS FY 2026 ICD-10-CM dataset · Effective Oct 1, 2025 – Sep 30, 2026

C90.02 is a billable ICD-10-CM diagnosis code for multiple myeloma in relapse. It is valid on HIPAA claims for fiscal year 2026 (October 1, 2025 through September 30, 2026) and groups to MS-DRG 820 through 825, 840 through 842. Coders also document this condition as relapse multiple myeloma. In AHRQ's Clinical Classifications Software (CCSR), this diagnosis falls under Multiple myeloma.

Code Identity

ICD-10-CM Code
C90.02
Billable Status
Yes — Valid for Submission
Code Describes
Multiple myeloma in relapse
Short Description
Multiple myeloma in relapse
Same as the full description in the CMS dataset.
Parent Code
C90.0
Multiple myeloma

Code Classification

ChapterC00–D49Neoplasms
SectionC81-C96Malignant neoplasms of lymphoid, hematopoietic and related tissue
CategoryC90Multiple myeloma and malignant plasma cell neoplasms
This CodeC90.02Multiple myeloma in relapse

Approximate SynonymsGuidance

Alternate terms and clinical phrases that map to this code.

  • Relapse multiple myeloma

Clinical ClassificationClinical

AHRQ’s CCSR groups this code into broader clinical categories.

CCSR NEO065
Multiple myeloma
Default principal diagnosis: inpatient Yes · outpatient Yes

Clinical InformationClinical

  • Multiple Myeloma

    a malignancy of mature plasma cells engaging in monoclonal immunoglobulin production. it is characterized by hyperglobulinemia, excess bence-jones proteins (free monoclonal immunoglobulin light chains) in the urine, skeletal destruction, bone pain, and fractures. other features include anemia; hypercalcemia; and renal insufficiency.

  • Smoldering Multiple Myeloma

    an asymptomatic and slow-growing plasma cell dyscrasia characterized by presence of myeloma proteins and clonal bone marrow plasma cells without end-organ damage (e.g., renal impairment). it is distinguished from monoclonal gammopathy of undetermined significance by a much higher risk of progression to symptomatic multiple myeloma.

Patient EducationClinical

Multiple Myeloma

Multiple myeloma is a cancer that begins in plasma cells, a type of white blood cell. These cells are part of your immune system, which helps protect the body from germs and other harmful substances. In time, myeloma cells collect in the bone marrow and in the solid parts of bones.

Read the full article at MedlinePlus

Courtesy of MedlinePlus, a service of the U.S. National Library of Medicine.

Convert C90.02 to ICD-9-CMHistory

The closest ICD-9-CM equivalents under the General Equivalence Mappings.

ICD-9-CM
203.02 Mult myeloma in relapse
Exact Match The mapping is direct, with no qualifiers.

Code HistoryHistory

FY 2016AddedAdded to the ICD-10-CM code setEffective October 1, 2015, the first year of ICD-10-CM.
FY 2017–2025No changes
FY 2026CurrentCurrent code set, no changesEffective October 1, 2025 through September 30, 2026.

Questions About C90.02Overview

Is C90.02 (Multiple myeloma) a billable code?

Yes. This is a billable ICD-10-CM code, specific enough to report multiple myeloma in relapse on HIPAA-covered claims from October 1, 2025 through September 30, 2026.

What MS-DRG does C90.02 group to?

When multiple myeloma in relapse is the principal diagnosis on an inpatient stay, it groups to MS-DRG 820, 821, 822, 823, 824, 825, 840, 841, 842, with relative weights from 1.0104 to 5.8648 depending on complications. Higher weights mean higher Medicare reimbursement.

What is the ICD-9 equivalent of C90.02?

Under the General Equivalence Mappings, multiple myeloma in relapse converts to ICD-9-CM 203.02 (mult myeloma in relapse). The mapping is a direct match.

Footnotes

[1] Chronic - a chronic condition code indicates a condition lasting 12 months or longer and its effect on the patient based on one or both of the following criteria:

  • The condition results in the need for ongoing intervention with medical products,treatment, services, and special equipment
  • The condition places limitations on self-care, independent living, and social interactions.